Labcorp Announces Clinical Availability of Liquid Biopsy Test to Guide Personalized Treatment Plans for Patients with Advanced Solid Tumors
Portfolio Pulse from
Labcorp has announced the clinical availability of its new liquid biopsy test, Labcorp® Plasma CompleteTM, which offers a genomic profiling solution for patients with advanced solid tumors. This test is based on circulating tumor DNA and can be conducted with a simple blood draw.
February 24, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Labcorp has introduced Labcorp® Plasma CompleteTM, a new liquid biopsy test for advanced solid tumors, enhancing its product offerings in genomic profiling.
The introduction of Labcorp® Plasma CompleteTM positions Labcorp as a leader in genomic profiling for cancer treatment, likely boosting its market position and revenue potential. This innovation could attract more oncologists to use Labcorp's services, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100